专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005080436A3 ANTIBODIES THAT BIND POTE AND USES THEREOF 审中-公开
标题翻译：抗体，其包装和其用途
公开(公告)号：WO2005080436A3
公开(公告)日：2007-12-06
申请号：PCT/US2005005419
申请日：2005-02-18
申请人： US GOV HEALTH & HUMAN SERV , PASTAN IRA H , BERA TAPAN , LEE BYUNGKOOK , NAGATA SATOSHI , ISE TOMOKO
发明人： PASTAN IRA H , BERA TAPAN , LEE BYUNGKOOK , NAGATA SATOSHI , ISE TOMOKO
IPC分类号： C07K16/18 , C07K14/47 , C07K16/30 , G01N33/574
CPC分类号： G01N33/574 , C07K14/47 , C07K16/30
摘要： POTE-21 and its paralogs are expressed in cancer, such as breast, prostate, lung, colon, pancreatic and ovarian cancer. Antibodies are disclosed herein that bind the N-terminal (extracellular) portion of POTE, or a paralog of POTE. These antibodies are of use in the detection and treatment of cancer. Methods for the treatment of cancer using a POTE polypeptide or fragment thereof are also described.
摘要翻译： POTE-21及其旁系同源物在癌症中表达，如乳腺癌，前列腺癌，肺癌，结肠癌，胰腺癌和卵巢癌。本文公开了结合POTE的N末端（细胞外）部分或POTE的旁系同源物的抗体。这些抗体可用于癌症的检测和治疗。还描述了使用POTE多肽或其片段治疗癌症的方法。

2. 发明申请

WO03062446A9 MRP9 AND ITS USE DETECTING AND TREATING CANCER 审中-公开
标题翻译： MRP9及其使用检测和治疗癌症
公开(公告)号：WO03062446A9
公开(公告)日：2004-03-04
申请号：PCT/US0301340
申请日：2003-01-15
申请人： US GOV HEALTH & HUMAN SERV , PASTAN IRA H , BERA TAPAN K , LEE BYUNGKOOK
发明人： PASTAN IRA H , BERA TAPAN K , LEE BYUNGKOOK
IPC分类号： C07K14/47 , C07K16/30 , C12Q1/68 , G01N33/574 , C12Q
CPC分类号： C07K14/4748 , A61K2039/505 , C07K16/3015 , C12Q1/6886 , C12Q2600/158 , G01N33/574
摘要： MPR9 is disclosed herein to be expressed in cancer cells. An antibody is disclosed that specifically binds an antigenic epitope of an MRP9 polypeptide. Methods are also provided for detecting cancer cells, by detecting a mRNA encoding MRP9, or by detecting MRP9 polypeptide. Immunotherapeutics are also provided that are based on MRP9. These immunotherapeutics are of use in the treatment of cancer.
摘要翻译： MPR9在本文中公开以在癌细胞中表达。公开了特异性结合MRP9多肽的抗原表位的抗体。还提供了通过检测编码MRP9的mRNA或通过检测MRP9多肽来检测癌细胞的方法。还提供了基于MRP9的免疫治疗剂。这些免疫治疗剂可用于治疗癌症。

3. 发明申请

WO02102985B1 PATE, A GENE EXPRESSED IN PROSTATE CANCER, PROSTATE AND TESTIS, AND USES THEREOF 审中-公开
标题翻译： PATE，在前列腺癌，前列腺癌和TESTIS中表达的基因及其用途
公开(公告)号：WO02102985B1
公开(公告)日：2004-05-27
申请号：PCT/US0219086
申请日：2002-06-14
申请人： US GOV HEALTH & HUMAN SERV , PASTAN IRA H , BERA TAPAN K , SALVATORE GUILIANA , VINCENT JAMES , LEE BYUNGKOOK
发明人： PASTAN IRA H , BERA TAPAN K , SALVATORE GUILIANA , VINCENT JAMES , LEE BYUNGKOOK
IPC分类号： C07K16/30 , C07K16/00 , G01N33/53
CPC分类号： C07K16/3069 , A61K2039/505
摘要： An antibody is disclosed that specifically binds a PATE polypeptide. A nucleic acid sequence is disclosed that includes a PATE promoter or a conservative variant thereof. Methods are also disclosed for detecting prostate cancer in a subject. In one embodiment, a method is disclosed for producing an immune response against a cell expressing a PATE polypeptide in a subject. In another embodiment, a method is disclosed for inhibiting the growth of a malignant cell expressing a PATE polypeptide. A method is also disclosed for reducing the number of prostate cancer cells in a subject that includes administering to the subject a therapeutically effective amount of the PATE polypeptide or a polynucleotide encoding the PATE polypeptide. Kits for detecting PATE polypeptides and PATE polynucleotides are disclosed. In one embodiment, these kits are ofuse to detect prostate cancer. A method is also disclosed for increasing the proliferation of a prostate cell. The method includes contacting the prostate cell with a PATE polypeptide or transfecting the prostate cell with a nucleic acid encoding the P ATE polypeptide, thereby increasing the proliferation of the prostate cell.
摘要翻译：公开了特异性结合PATE多肽的抗体。公开了包含PATE启动子或其保守变体的核酸序列。还公开了用于检测受试者中前列腺癌的方法。在一个实施方案中，公开了用于产生针对受试者中表达PATE多肽的细胞的免疫应答的方法。在另一个实施方案中，公开了抑制表达PATE多肽的恶性细胞生长的方法。还公开了一种减少受试者中前列腺癌细胞数量的方法，其包括向受试者施用治疗有效量的PATE多肽或编码PATE多肽的多核苷酸。公开了用于检测PATE多肽和PATE多核苷酸的试剂盒。在一个实施方案中，这些试剂盒可用于检测前列腺癌。还公开了用于增加前列腺细胞增殖的方法。该方法包括使前列腺细胞与PATE多肽接触或用编码P ATE多肽的核酸转染前列腺细胞，从而增加前列腺细胞的增殖。

4. 发明申请

WO0218584A3 XAGE-1, A GENE EXPRESSED IN MULTIPLE CANCERS, AND USES THEREOF 审中-公开
标题翻译： XAGE-1，多基因中表达的基因及其用途
公开(公告)号：WO0218584A3
公开(公告)日：2003-01-16
申请号：PCT/US0127258
申请日：2001-08-31
申请人： US GOV HEALTH & HUMAN SERV , PASTAN IRA H , LIU XIU FEN , BERA TAPAN K , LEE BYUNGKOOK , EGLAND KRISTI A
发明人： PASTAN IRA H , LIU XIU FEN , BERA TAPAN K , LEE BYUNGKOOK , EGLAND KRISTI A
IPC分类号： A61K38/00 , C07K14/47 , C12N15/12 , A61K31/7088 , A61K38/17 , C07K16/18 , C12Q1/68
CPC分类号： C07K14/4748 , A61K38/00
摘要： The invention relates to the surprising discovery that XAGE-1 is translated as two proteins, a 9 kD protein, termed p9, and a 16.3 kD protein, termed p16. The invention further relates to the surprising discovery that XAGE-1 is expressed in a number of important human cancers, specifically: prostate cancer, lung cancer, ovarian cancer, breast cancer, glioblastoma, pancreatic cancer, T cell lymphoma, melanoma, and histocytic lymphoma. The proteins p9 and p16, immunogenic fragments thereof, analogs of these proteins, and nucleic acids encoding these proteins, fragments, or analogs, can be administered to persons with XAGE-1 expressing cancers to raise or augment an immune response to the cancer. The invention further provides nucleic acid sequences encoding the proteins, as well as expression vectors, host cells, and antibodies to the proteins. Further, the invention provides immunoconjugates that comprise an antibody to p16 or to p9, and an effector molecule, such as a label, a radioisotope, or a toxin. The invention also provides methods of inhibiting the growth of XAGE-1 expressing cells by contacting them with immunoconjugates comprising an anti- p9 or p16 antibody and a toxic moiety. Further, the invention provides kits for detecting the presence of p9 or p16 in a sample.
摘要翻译：本发明涉及令人惊奇的发现，即XAGE-1被翻译为两种蛋白质，称为p9的9kD蛋白质，称为p16的16.3kD蛋白质。本发明还涉及令人惊奇的发现：XAGE-1在许多重要的人类癌症中表达，特别是前列腺癌，肺癌，卵巢癌，乳腺癌，成胶质细胞瘤，胰腺癌，T细胞淋巴瘤，黑素瘤和组织细胞淋巴瘤。蛋白质p9和p16，其免疫原性片段，这些蛋白质的类似物，以及编码这些蛋白质，片段或类似物的核酸可以被给予具有XAGE-1表达癌症的人，以提高或增加对癌症的免疫应答。本发明还提供编码蛋白质的核酸序列，以及表达载体，宿主细胞和对蛋白质的抗体。此外，本发明提供包含对p16或p9的抗体的免疫缀合物和效应分子，例如标记物，放射性同位素或毒素。本发明还提供了通过使它们与包含抗p9或p16抗体和毒性部分的免疫缀合物接触来抑制表达XAGE-1细胞生长的方法。此外，本发明提供了用于检测样品中p9或p16的存在的试剂盒。

5. 发明申请

WO0236623A2 GHEP, A GENE HIGHLY EXPRESSED IN NORMAL AND NEOPLASTIC PROSTATE, AND USES THEREFOR 审中-公开
标题翻译： GHEP，一种在正常和神经前体中高度表达的基因及其用途
公开(公告)号：WO0236623A2
公开(公告)日：2002-05-10
申请号：PCT/US0142627
申请日：2001-10-10
申请人： US GOV HEALTH & HUMAN SERV , PASTAN IRA H , OLSSON PAR , BERA TAPAN K , ESSAND MAGNUS , LEE BYUNGKOOK
发明人： PASTAN IRA H , OLSSON PAR , BERA TAPAN K , ESSAND MAGNUS , LEE BYUNGKOOK
IPC分类号： C07K14/47 , C12N15/12
CPC分类号： C07K14/47
摘要： The invention provides a Gene Highly Expressed in Prostate ("GHEP"). The gene is found in normal and neoplastic prostate, and encodes two short proteins, one 34 amino acids ("ghep34") in length and one 35 amino acids in length ("ghep35"). Detection of the transcript or of the proteins in tissues other than the prostate, liver, or salivary gland is indicative of prostate cancer. The nucleic acids, proteins, and immunogenic fragments thereof can be used to raise an immune response to prostate cancer. The invention further provides methods of detecting the proteins or the gene transcript in a biological sample. If the biological sample is from a tissue other than the prostate, liver or salivary gland, detection of either of the protein or of the gene transcript is indicative of the presence of prostate cancer in the subject from whom the sample was taken. The invention further provides antibodies which specifically recognize ghep34 and antibodies which specifically recognize ghep35, as well as kits for the detection of one or both of the proteins in a sample.
摘要翻译：本发明提供了在前列腺中表达高表达的基因（“GHEP”）。该基因位于正常和肿瘤前列腺中，并编码长度为34个氨基酸（“ghep34”）和长度为35个氨基酸（“ghep35”）的两个短蛋白质。检测前列腺，肝脏或唾液腺以外的组织中的转录物或蛋白质是前列腺癌的指示。核酸，蛋白质和其免疫原性片段可用于提高对前列腺癌的免疫应答。本发明还提供了检测生物样品中的蛋白质或基因转录物的方法。如果生物样品来自除了前列腺，肝脏或唾液腺以外的组织，检测蛋白质或基因转录物中的任何一个表明在取样的受试者中存在前列腺癌。本发明还提供了特异性识别ghep34的抗体和特异性识别ghep35的抗体，以及用于检测样品中的一种或两种蛋白质的试剂盒。

6. 发明申请

WO0240545A9 REDUCTION OF THE NONSPECIFIC ANIMAL TOXICITY OF IMMUNOTOXINS BY MUTATING THE FRAMEWORK REGIONS OF THE FV TO LOWER THE ISOELECTRIC POINT 审中-公开
标题翻译：通过打破FV的框架区域来降低免疫动力学的非特异性动物毒性以降低ISOELECTRIC POINT
公开(公告)号：WO0240545A9
公开(公告)日：2003-02-06
申请号：PCT/US0143602
申请日：2001-11-16
申请人： US GOV HEALTH & HUMAN SERV , PASTAN IRA H , ONDA MASANORI , NAGATA SATOSHI , TSUTSUMI YASUO , VINCENT JAMES J , KREITMAN ROBERT J , VASMATZIS GEORGE , LEE BYUNGKOOK
发明人： PASTAN IRA H , ONDA MASANORI , NAGATA SATOSHI , TSUTSUMI YASUO , VINCENT JAMES J , KREITMAN ROBERT J , VASMATZIS GEORGE , LEE BYUNGKOOK
IPC分类号： A61K47/48 , A61P35/00 , C07K14/21 , C07K16/00 , C07K16/18 , C07K16/28 , C07K16/30 , C12N1/21 , C07K19/00 , C12N15/62 , C12N15/70
CPC分类号： C07K16/28 , A61K47/6829 , A61K47/6849 , A61K47/6867 , A61K2039/505 , C07K14/21 , C07K16/00 , C07K16/18 , C07K16/2803 , C07K16/2866 , C07K16/2896 , C07K16/30 , C07K2317/56 , C07K2317/567 , C07K2317/624 , C07K2319/02
摘要： The invention provides recombinant immunotoxins that have been modified from a parental immunotoxin to lower liver toxicity. The immunotoxins are created by specifically mutating charged residues in the framework regions of the heavy chain, the light chain, or both, of the antibody portion or antigen-binding fragment thereof of the parental immunotoxin to reduce the pI of the antibody or fragment. In preferred forms, the antibody portion of the parental is an anti-Tac, anti-mesothelin, or anti-LewisY antigen antibody or antigen-binding fragment, and in particularly preferred forms the antibody portion is an M16 dsFv, a St6 dsFv or a Mt9 dsFv, or a sequence that has at least 90% sequence identity to one of these molecules but retain the particular mutations that lower pI without affecting antibody activity. The invention further provides nucleic acids encoding the recombinant immunotoxins of the invention, expression cassettes comprising the nucleic acids, and host cells comprising the expression cassettes. The invention also provides a method for killing a cell comprising an antigen on the surface of the cell, the method comprising contacting the cell with a recombinant immunotoxin of the invention that has an antibody or antigen-binding fragment thereof that binds specifically to the antigen on the surface of the cell, and uses of immunotoxins of the invention for the manufacture of medicaments.
摘要翻译：本发明提供已经从亲本免疫毒素修饰以降低肝毒性的重组免疫毒素。免疫毒素通过在亲本免疫毒素的抗体部分或其抗原结合片段的重链，轻链或两者的构架区中特异性突变带电残基而产生，以减少抗体或片段的pI。在优选形式中，亲本的抗体部分是抗Tac，抗间皮素或抗LewisY抗原抗体或抗原结合片段，并且在特别优选的形式中，抗体部分是M16 dsFv，St6 dsFv或 Mt9 dsFv或与这些分子之一具有至少90％序列同一性的序列，但保留降低pI而不影响抗体活性的特定突变。本发明还提供编码本发明的重组免疫毒素的核酸，包含核酸的表达盒和包含表达盒的宿主细胞。本发明还提供了一种用于杀死细胞表面上包含抗原的细胞的方法，所述方法包括使细胞与本发明的重组免疫毒素接触，所述重组免疫毒素具有抗体或其抗原结合片段，其特异性与抗原结合细胞的表面，以及本发明的免疫毒素用于制备药物的用途。

7. 发明申请

WO0195942A3 PEGYLATION OF LINKERS IMPROVES ANTITUMOR ACTIVITY AND REDUCES TOXICITY OF IMMUNOCONJUGATES 审中-公开
标题翻译：链接的聚合改善抗肿瘤活性并降低免疫球蛋白的毒性
公开(公告)号：WO0195942A3
公开(公告)日：2003-07-31
申请号：PCT/US0118503
申请日：2001-06-08
申请人： US GOV HEALTH & HUMAN SERV , PASTAN IRA H , TSUTSUMI YASUO , ONDA MASANORI , NAGATA SATOSHI , LEE BYUNGKOOK , KREITMAN ROBERT J
发明人： PASTAN IRA H , TSUTSUMI YASUO , ONDA MASANORI , NAGATA SATOSHI , LEE BYUNGKOOK
IPC分类号： A61K38/00 , A61K39/395 , A61K47/48 , A61P35/00 , A61P43/00
CPC分类号： A61K47/6849 , A61K47/6829
摘要： The present invention is directed to the site-specific PEGylation of immunoconjugates. In particular, the present invention provides immunoconjugates wherein a connector molecule attaching a targeting molecule to an effector molecule is conjugated to one or more polyethylene glycol molecules. The present invention further provides methods for increasing the antitumor activity of an immunotoxin, comprising attaching in a site-specific manner one or more polyethylene glycol molecules to a linker connecting a toxic moiety to a targeting moiety of an immunotoxin.
摘要翻译：本发明涉及免疫缀合物的位点特异性PEG化。特别地，本发明提供免疫偶联物，其中将靶向分子连接至效应分子的连接分子与一个或多个聚乙二醇分子缀合。本发明还提供了增加免疫毒素的抗肿瘤活性的方法，包括以位点特异性方式将一个或多个聚乙二醇分子连接到将毒性部分连接到免疫毒素的靶向部分的连接体上。

8. 发明申请

WO0240545A2 REDUCTION OF THE NONSPECIFIC ANIMAL TOXICITY OF IMMUNOTOXINS BY MUTATING THE FRAMEWORK REGIONS OF THE FV TO LOWER THE ISOELECTRIC POINT 审中-公开
标题翻译：通过打破FV的框架区域来降低免疫动力学的非特异性动物毒性以降低ISOELECTRIC POINT
公开(公告)号：WO0240545A2
公开(公告)日：2002-05-23
申请号：PCT/US0143602
申请日：2001-11-16
申请人： US GOV HEALTH & HUMAN SERV , PASTAN IRA H , ONDA MASANORI , NAGATA SATOSHI , TSUTSUMI YASUO , VINCENT JAMES J , KREITMAN ROBERT J , VASMATZIS GEORGE , LEE BYUNGKOOK
发明人： PASTAN IRA H , ONDA MASANORI , NAGATA SATOSHI , TSUTSUMI YASUO , VINCENT JAMES J , KREITMAN ROBERT J , VASMATZIS GEORGE , LEE BYUNGKOOK
IPC分类号： A61K47/48 , A61P35/00 , C07K14/21 , C07K16/00 , C07K16/18 , C07K16/28 , C07K16/30 , C12N1/21 , C07K19/00 , C12N15/62 , C12N15/70
CPC分类号： C07K16/28 , A61K47/6829 , A61K47/6849 , A61K47/6867 , A61K2039/505 , C07K14/21 , C07K16/00 , C07K16/18 , C07K16/2803 , C07K16/2866 , C07K16/2896 , C07K16/30 , C07K2317/56 , C07K2317/567 , C07K2317/624 , C07K2319/02
摘要： The invention provides recombinant immunotoxins that have been modified from a parental immunotoxin to lower liver toxicity. The immunotoxins are created by specifically mutating charged residues in the framework regions of the heavy chain, the light chain, or both, of the antibody portion or antigen-binding fragment thereof of the parental immunotoxin to reduce the pI of the antibody or fragment. In preferred forms, the antibody portion of the parental is an anti-Tac, anti-mesothelin, or anti-LewisY antigen antibody or antigen-binding fragment, and in particularly preferred forms the antibody portion is an M16 dsFv, a St6 dsFv or a Mt9 dsFv, or a sequence that has at least 90% sequence identity to one of these molecules but retain the particular mutations that lower pI without affecting antibody activity. The invention further provides nucleic acids encoding the recombinant immunotoxins of the invention, expression cassettes comprising the nucleic acids, and host cells comprising the expression cassettes. The invention also provides a method for killing a cell comprising an antigen on the surface of the cell, the method comprising contacting the cell with a recombinant immunotoxin of the invention that has an antibody or antigen-binding fragment thereof that binds specifically to the antigen on the surface of the cell, and uses of immunotoxins of the invention for the manufacture of medicaments.
摘要翻译：本发明提供已经从亲本免疫毒素修饰以降低肝毒性的重组免疫毒素。免疫毒素通过在亲本免疫毒素的抗体部分或其抗原结合片段的重链，轻链或两者的构架区中特异性突变带电残基而产生，以减少抗体或片段的pI。在优选形式中，亲本的抗体部分是抗Tac，抗间皮素或抗LewisY抗原抗体或抗原结合片段，并且在特别优选的形式中，抗体部分是M16 dsFv，St6 dsFv或 Mt9 dsFv或与这些分子之一具有至少90％序列同一性的序列，但保留降低pI而不影响抗体活性的特定突变。本发明还提供编码本发明的重组免疫毒素的核酸，包含核酸的表达盒和包含表达盒的宿主细胞。本发明还提供了一种用于杀死细胞表面上包含抗原的细胞的方法，所述方法包括使细胞与本发明的重组免疫毒素接触，所述重组免疫毒素具有抗体或其抗原结合片段，其特异性与抗原结合细胞的表面，以及本发明的免疫毒素用于制备药物的用途。

9. 发明申请

WO2007016150A3 MUTATED PSEUDOMONAS EXOTOXINS WITH REDUCED ANTIGENICITY 审中-公开
标题翻译：具有降低抗原性的突变假单孢菌外毒素
公开(公告)号：WO2007016150A3
公开(公告)日：2007-08-09
申请号：PCT/US2006028986
申请日：2006-07-25
申请人： US GOV HEALTH & HUMAN SERV , PASTAN IRA H , ONDA MASANORI , NAGATA SATOSHI , FITZGERALD DAVID , KREITMAN ROBERT , LEE BYUNGKOOK
发明人： PASTAN IRA H , ONDA MASANORI , NAGATA SATOSHI , FITZGERALD DAVID , KREITMAN ROBERT , LEE BYUNGKOOK
IPC分类号： C07K14/195 , A61K38/16 , A61K47/48 , C07K14/21 , C07K19/00
CPC分类号： A61K47/48484 , A61K38/00 , A61K47/6829 , C07K14/21 , C07K2319/33
摘要： The invention provides mutated Pseudomonas exotoxins (PE) that have reduced immunogenicity compared to PEs containing the native sequence. The PEs of the invention have one or more individual mutations of positions of the native sequence of PE that reduce antibody binding to one or more PE epitopes. Nucleic acids encoding the mutated PEs, chimeric molecules comprising them, compositions comprising the chimeric molecules and methods of using them, are also provided.
摘要翻译：本发明提供与含有天然序列的PE相比具有降低的免疫原性的突变假单胞菌外毒素（PE）。本发明的PE具有减少抗体与一个或多个PE表位结合的PE天然序列位置的一个或多个单独突变。还提供了编码突变PE的核酸，包含它们的嵌合分子，包含嵌合分子的组合物和使用它们的方法。

10. 发明申请

WO2004092213B1 GENE EXPRESSED IN PROSTATE CANCER, METHODS AND USE THEREOF 审中-公开
标题翻译：在前列腺癌中表达的基因，方法和用途
公开(公告)号：WO2004092213B1
公开(公告)日：2005-01-06
申请号：PCT/US2004010588
申请日：2004-04-05
申请人： US GOV HEALTH & HUMAN SERV , PASTAN IRA , BERA TAPAN K , LEE BYUNGKOOK
发明人： PASTAN IRA , BERA TAPAN K , LEE BYUNGKOOK
IPC分类号： A61K38/00 , A61K38/16 , A61K47/48 , C07K14/47 , C12Q1/68 , G01N33/574
CPC分类号： A61K38/168 , A61K38/164 , A61K47/64 , C07K14/47 , C07K14/4748 , C12Q1/6886 , C12Q2600/106 , G01N33/57434 , G01N2500/00
摘要： A polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Splice Variant-Novel Gene Expressed in Prostate (SV-NGEP). Polynucleotides encoding SV-NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies and immunoconjugates are disclosed that specifically bind SV-NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds SV-NGEP, or a polynucleotide encoding SV-NGEP. Assays are disclosed for the detection prostate cancer. Pharmaceutical compositions including an SV-NGEP polypeptide, an antibody that specifically binds SV-NGEP, or a polynucleotide encoding SV-NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer.
摘要翻译：公开了在前列腺细胞中特异性检测到的多肽，称为前列腺中表达的剪接变体 - 新型基因（SV-NGEP）。还公开了编码SV-NGEP的多核苷酸，以及包括这些多核苷酸的载体。还公开了用这些多核苷酸转化的宿主细胞。公开了特异性结合SV-NGEP的抗体和免疫偶联物。公开了使用NGEP多肽，特异性结合SV-NGEP的抗体或编码SV-NGEP的多核苷酸的方法。公开了检测前列腺癌的检测。还公开了包含SV-NGEP多肽，特异性结合SV-NGEP的抗体或编码SV-NGEP的多核苷酸的药物组合物。这些药物组合物可用于治疗前列腺癌。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式